Sandoz announces agreement to acquire CIMERLI ® business from Coherus, strengthening position in US market

CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Basel, January 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI®*…#basel #sandoz #coherusbiosciences #kerenharuvi #sandoznorthamerica #fda #dme #rvo #vegf #endophthalmitis
Source: Reuters: Health - Category: Consumer Health News Source Type: news